5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Alembic Pharmaceuticals Ltd.

•
alembicpharmaceuticals.comBSE: 533573NSE: APLLTD
Market Cap₹ 16,075 Cr.
Current Price
High / Low₹ 998 / 636
Stock P/E23.2
Book Value₹ 297
Price to Book2.29
Dividend Yield1.47 %
ROCE11.7 %
ROE12.3 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Formulations: 83.8% • Active Pharmaceutical Ingredients (API): 16.2%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has consistently been profitable over the last 5 years
  • Company has been maintaining a healthy dividend payout of 35.0%
  • Company has a consistent dividend-paying track record
  • Stock looks reasonably valued - P/E of 23.2 is below its historical median
  • Company comfortably covers its interest (8.4x coverage)
  • Company generates healthy free cash flow

CONS

  • Company has delivered a poor profit growth of -9.7% over past five years
  • Recurring exceptional / one-off items are inflating headline profit
  • Operating margins have contracted to 7.8% from 12.6%
  • Company has delivered a poor sales growth of 6.4% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.APLLTD817.8023.1816074.931.47172.3612.192149.7725.6611.7415.46
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,8761,8482,150
1,2871,3871,3641,2571,3251,4091,4331,4981,4291,5941,5831,6201,943
Operating Profit199208266260237239260272281316294228207
OPM %13.37%13.06%16.34%17.14%15.16%14.52%15.37%15.37%16.45%16.53%15.64%12.34%9.61%
121034230101467-27115
Interest14161511131922252424232328
Depreciation66686969697170697476808998
Profit before Tax130135185183157180177193191222163118222
Tax %7.06%-1.43%2.24%2.53%14.35%15.19%22.59%18.33%19.14%18.00%18.09%-70.56%22.31%
Net Profit0000135153138157154184132202172
6.146.959.189.076.847.797.017.987.859.406.7610.318.80

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
3,1353,1313,9354,6065,3935,3065,6536,2296,6727,3457,784
2,5202,5163,0793,3923,9134,4324,9455,2965,6696,2276,740
Operating Profit6156158561,2141,4808747089331,0031,1181,044
OPM %19.61%19.65%21.75%26.36%27.44%16.48%12.53%14.97%15.03%15.22%13.41%
33527-30875032961-12-4
Interest53182716185056799498
Depreciation83105115157183287275273279319342
Profit before Tax5295417491,0001,368625355632707694725
Tax %23.09%22.24%20.92%19.92%18.52%16.70%3.55%2.53%17.70%3.33%4.99%
Net Profit4074215938011,115521342616582671689
EPS21.3921.8931.0043.9759.1826.5017.4031.3329.6834.33—
Dividend Payout %18.70%18.27%17.74%22.74%24.00%37.73%45.98%35.11%37.06%34.95%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
6%
3 Years:
9%

COMPOUNDED PROFIT GROWTH

10 Years:
-1%
5 Years:
-10%
3 Years:
25%

STOCK PRICE CAGR

10 Years:
3%
5 Years:
1%
3 Years:
2%
1 Year:
-14%

RETURN ON EQUITY

10 Years:
18%
5 Years:
11%
3 Years:
12%
Last Year:
12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jul 29

₹ 6

Rs.12.0000 per share(600%)Final Dividend

2025

Jul 29

₹ 5.50

Rs.11.0000 per share(550%)Final Dividend

2024

Jul 15

₹ 5.50

Rs.11.0000 per share(550%)Final Dividend

2023

Jul 28

₹ 4

Rs.8.0000 per share(400%)Final Dividend

2022

Aug 17

Interim Dividend

2021

Jul 19

₹ 7

Rs.14.0000 per share(700%)Dividend

2019

Jul 18

₹ 2.75

Rs.5.5000 per share(275%)Dividend

2018

Jul 18

₹ 2

Rs.4.0000 per share(200%)Dividend

2017

Jul 11

₹ 2

Rs.4.0000 per share(200%)Dividend

2016

Jul 20

₹ 2

Rs.4.0000 per share(200%)Dividend

2022

May 2

₹ 5

Rs.10.0000 per share(500%)Dividend

2026

Jul 10

₹ 6

Rs.12.0000 per share(600%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital38383838393939393939
Minority Interest00-1-290000-1-6
1,8652,1822,6813,1825,0285,1984,3314,7795,1525,636
897089281,8212715027054931,2421,565
Trade Payables501759644626669706680736880835
319376661554954784308294397516
Total Liabilities2,8114,0644,9526,1926,9617,2306,0646,3417,7098,586
7999931,1581,5521,7881,7982,3982,5472,5243,081
Capital Work in Progress3699111,3411,5741,9442,206601524837634
504249182361189693127141
6337349671,1881,4861,6101,4751,6442,2882,511
00000001,0251,4001,466
Cash & Bank1609020681106698212790203
8001,2941,2301,7801,4001,4291,410382443551
Total Assets2,8114,0644,9526,1926,9617,2306,0646,3417,7098,586

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4474489786851,70967678580388783
Cash from Investing-486-884-756-732-839-372-448-321-568-506
Cash from Financing-12950359155-597-217-262-438444-164
-286-69115-12827-371445-37113

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
69.6169.6169.6169.6769.6769.7469.7469.7469.87
4.323.944.173.943.964.054.234.264.17
15.4716.0516.0516.4316.4616.3016.1716.1715.93
Government0.000.000.000.000.000.000.000.000.00
10.6010.4010.169.969.909.929.869.8310.01

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
General Updates

2026-09-07 - Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Wholly Owned Subsidiary Company

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-08-25
Copy of Newspaper Publication

2026-08-25 - Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-20
Change in Company Secretary/Compliance Officer

2026-08-20 - Alembic Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer

2026-08-11
Copy of Newspaper Publication

2026-08-11 - Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-10
Resignation of Director/KMP/SMP

2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP

2026-08-10
Resignation

2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange regarding Resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer of the company w.e.f. August 11, 2026.

2026-08-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - Alembic Pharmaceuticals Limited has informed the Exchange about Transcript

News

Recent coverage and analyst commentary for APLLTD

Loading news…

🤖

AI Stock Analyst

Alembic Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login